参考文献/References:
[1] Yu Y,Gupta A,Wu C,et al.Characteristics,management,and outcomes of patientshospitalized for heart failure in china: the China peace retrospective heart failure study[J].J Am Heart Assoc,2019,8(17):e012884.
[2] Yancy CW,Jessup M,Bozkurt B,et al.2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J] .Circulation,2013,128(16):e240-327.
[3] Maggioni AP,Dahlstrom U,Filippatos G,et al.EURObservational research programme: regional differences and 1-year follow-up results of the heart failure pilot survey (ESC-HF pilot)[J].Eur J Heart Failure,2013,15(7):808-817.
[4] Jaisser F,Farman N.Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology[J].Pharmacol Rev,2016,68(1):49-75.
[5] Capelli I,Gasperoni L,Ruggeri M,et al.New mineralocorticoid receptor antagonists:update on their use in chronic kidney disease and heart failure[J].J Nephrol,2020,33(1):37-48.
[6] Pitt B,Pedro Ferreira J,Zannad F.Mineralocorticoid receptor antagonists in patients with heart failure: Current experience and future perspectivesl[J].Eur Heart J Cardiovasc Pharmacother,2017,3(1):48-57.
[7] Ponikowski P,Voors AA,Anker SD,et al.2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC).Developed with the special contribution of the Heart Failure Association(HFA) of the ESC[J].Eur J Heart Fail ,2016,18(8):891-975.
[8] Parthasarathy HK,Menard J,White WB,et al.A double-blind,randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism[J].J Hypertens,2011,29(5):980-990.
[9] Barfacker L,Kuhl A,Hillisch A,et al.Discovery of bay 94-8862:a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases[J].ChemMedChem,2012,7(8):1385-1403.
[10] Kolkhof P,Nowack C,Eitner F.Nonsteroidal antagonists of the mineralocorticoid receptor[J].Curr Opin Nephrol Hypertens,2015,24(5):417-424.
[11] Amazit L,le Billan F,Kolkhof P,et al.Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1[J].J Biol Chem,2015,290(36):21876-21889.
[12] Kolkhof P,Delbeck M,Kretschmer A,et al.Finerenone,a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury[J].J Cardiovasc Pharmacol,2014,64(1):69-78.
[13] Liu LC,Schutte E,Gansevoort RT,et al.Finerenone:third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease[J].Expert Opin Investig Drugs,2015,24(8):1123-1135.
[14] Heinig R,Gerisch M,Engelen A,et al.Pharmacokinetics of the novel,selective,non-steroidal mineralocorticoid receptor antagonist finerenone in healthy volunteers:results from an absolute bioavailability study and drug-drug interaction studies in vitro and in vivo[J].Eur J Drug Metab Pharmacokine,2018,43(6):715-727.
[15] Kolkhof P,Borden SA.Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics[J].Mol Cell Endocrinol,2012,350(2):310-317.
[16] Pitt B,Kober L,Ponikowski P,et al.Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist bay 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease:a randomized,double-blind trial[J].Eur Heart J, 2013,34(31):2453-2463.
[17] Heinig R,Lambelet M,Nagelschmitz J,et al.Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (bay 94-8862) in individuals with mild or moderate hepatic impairment[J].Eur J Drug Metab Pharmacokinet ,2019,44(5):619-628.
[18] Heinig R,Kimmeskamp-Kirschbaum N,Halabi A,et al.Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with renal impairment[J].Clin Pharmacol Drug Dev,2016,5(6):488-501.
[19] Gueret A,Harouki N,Favre J,et al.Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction[J].Hypertension,2016,67(4):717-723.
[20] Pitt B,White H,Nicolau J,et al.Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure[J].J Am Coll Cardiol,2005,46(3):425-431.
[21] Zannad F,McMurray JJ,Krum H,et al.Eplerenone in patients with systolic heart failure and mild symptoms[J].N Engl J Med ,2011,364(1):11-21.
[22] Samuel JL,Delcayre C.Heart failure:aldosterone antagonists are underused by clinicians[J].Nat Rev Cardiol,2010,7(3):125-127.
[23] Pitt B,Anker SD,Bohm M,et al.Rationale and design of mineralocorticoid receptor antagonist tolerability study-heart failure (ARTS-HF):a randomized study of finerenone vs .Eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease[J].Eur J Heart Fail,2015,17(2):224-232.
[24] Pei H,Wang W,Zhao D,et al.The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure:a systematic review and meta-analysis[J] .Medicine,2018,97(16):e0254.
[25] Lentini S,Heinig R,Kimmeskamp-Kirschbaum N,et al.Pharmacokinetics,safety and tolerability of the novel,selective mineralocorticoid receptor antagonist finerenone—results from first-in-man and relative bioavailability studies[J].Fundam Clin Pharmacol,2016,30(2):172-184.
[26] Pitt B,Filippatos G,Gheorghiade M,et al.Rationale and design of ARTS:a randomized ,double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease[J].Eur J Heart Fail,2012,14(6):668-675.
[27] Fonarow GC,Yancy CW,Albert NM,et al.Heart failure care in the outpatient cardiology practice setting:findings from IMPROVE HF[J].Circ Heart Fail,2008,1(2):98-106.
[28] Vardeny O,Claggett B,Anand I,et al.Incidence,predictors,and outcomes related to hypo-and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist[J].Circ Heart Fail,2014,7(4):573-579.
[29] Ruilope LM,Agarwal R,Chan JC,et al.Rationale,design,and baseline characteristics of ARTS-DN:a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy[J] .Am J Nephrol,2014,40(6):572-581.
[30] 谭漪扬,周建中.慢性心力衰竭治疗新进展—LCZ696 [J].心血管病学进展 ,2016,37(1):42-45.
[31] 朱永翔,李烽,张耀庭,等.沙库巴曲缬沙坦在射血分数降低性心力衰竭患者治疗中的研究进展[J].心血管病学进展,2019,40(9):1249-1252.